8-K: BIOLASE Reports Preliminary 2023 Revenue Growth and Outlines 2024 Outlook

BIOLASE announced preliminary unaudited revenue growth for 2023 and provided an optimistic outlook for 2024, including revenue growth and improved profitability.

Summary

• BIOLASE expects full-year 2023 revenue to be between $48.9 million and $49.2 million, representing a 1% increase over 2022.
• Approximately 71% of U.S. Waterlase sales in 2023 came from new customers.
• The company achieved a 45% sales conversion rate in 2023 due to the success of its Waterlase Trial Program.
• Consumable sales increased by approximately 20% in 2023 compared to 2022.
• BIOLASE anticipates full-year 2024 revenue to grow between 6% and 8%, reaching $52 million to $53 million.
• The company aims to improve its loss from operations by 50% to 60% in 2024.
• BIOLASE expects to achieve positive adjusted EBITDA for the full year of 2024.
• A 15% workforce reduction in January 2024 is projected to save approximately $2.5 million annually.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with revenue growth and profitability improvements expected. However, the preliminary nature of the results and the need for cost-cutting measures temper the overall sentiment.

Positives

• BIOLASE achieved revenue growth in 2023 despite industry headwinds.
• The company experienced a significant increase in new customers for its Waterlase product.
• BIOLASE's consumable sales saw substantial growth in 2023.
• The Waterlase Trial Program has been successful in increasing sales conversions.
• The company is taking steps to improve its cost structure and achieve profitability.
• BIOLASE has a strong intellectual property portfolio and is well-positioned to capitalize on market opportunities.
• The company has a clear plan for growth in 2024, including revenue targets and profitability goals.

Negatives

• The 2023 revenue growth was only 1%, which may be considered low by some investors.
• The company is still operating at a loss, although they are projecting a significant improvement in 2024.
• The preliminary revenue results are unaudited and subject to change.
• The company had to reduce its workforce by 15% to improve its cost structure.

Risks

• The preliminary revenue results are subject to change and may differ materially from the final results.
• The company's ability to achieve its 2024 revenue and profitability goals is subject to various market and operational risks.
• The company's financial statements are still being finalized and may require adjustments.
• There is no guarantee that the company will be able to achieve positive adjusted EBITDA in 2024.
• The company's future performance is subject to risks and uncertainties described in their SEC filings.

Future Outlook

BIOLASE anticipates continued revenue growth in 2024, with a focus on improving profitability and achieving positive adjusted EBITDA. The company plans to expand its educational offerings and increase the efficiency of its sales programs.

Management Comments

• The company believes its revenue-generating strategies and prudent management of its expenses will enable it to achieve its sales and profitability goals in 2024.
• BIOLASE is committed to advancing the field of dentistry through cutting-edge laser solutions while achieving profitability.

Industry Context

The dental laser market is growing, and BIOLASE is positioning itself as a leader in this space. The company's focus on education and training, along with its innovative products, is aimed at increasing adoption of laser dentistry among practitioners.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, BIOLASE's 1% revenue growth in 2023 is modest compared to some high-growth medical device companies.
• The company's focus on new customer acquisition (71% of U.S. Waterlase sales) suggests a strong market penetration strategy.
• The 20% growth in consumable sales indicates a recurring revenue stream, which is a positive sign for long-term sustainability.
• The projected 6-8% revenue growth for 2024 is a reasonable target, but will need to be compared to industry benchmarks when full results are released.
• The goal of achieving positive adjusted EBITDA in 2024 is a key indicator of financial health and will be closely watched by investors.

Stakeholder Impact

• Shareholders may view the preliminary results and 2024 outlook positively, but will be closely watching the company's progress towards profitability.
• Employees may be impacted by the workforce reduction, but the company's focus on growth and profitability could lead to future opportunities.
• Customers may benefit from the company's expanded educational offerings and improved products.
• Suppliers may see increased demand as the company grows its sales.
• Creditors will be interested in the company's progress towards achieving positive adjusted EBITDA.

Next Steps

• The company will report its fourth quarter and full-year 2023 financial results in March 2024.
• BIOLASE plans to continue expanding its educational offerings and increasing the efficiency of its sales programs in 2024.
• The company will focus on growing its DSO customer base and further penetrating the DSO market.

Key Dates

Keywords

dental lasers, BIOLASE, revenue growth, profitability, Waterlase, dental technology, medical devices, EBITDA, cost savings, consumables